Close Menu

NEW YORK – Evotec said today that it has acquired certain assets from Ncardia related to the use of induced pluripotent stem cells for drug discovery.

The assets include intellectual property relevant to iPSC-based phenotypic drug discovery and an existing undisclosed product business around iPSC-derived cells. Evotec said it is also taking on 17 stem cell biology experts operating out of laboratories at the BioCampus Cologne in Germany.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.